MedTrace Logo

Combination Chemotherapy in Treating Patients With Previously Untreated Advanced Hodgkin's Lymphoma

NCT00041210 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 850

Last updated 2013-09-20

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective in treating patients who have advanced Hodgkin's lymphoma.

PURPOSE: Randomized phase III trial to compare the effectiveness of two different combination chemotherapy regimens in treating patients who have advanced Hodgkin's lymphoma.

Conditions

Interventions

BIOLOGICAL

bleomycin sulfate

DRUG

ABVD regimen

DRUG

Stanford V regimen

DRUG

dacarbazine

DRUG

doxorubicin hydrochloride

DRUG

etoposide

DRUG

mechlorethamine hydrochloride

DRUG

prednisone

DRUG

vinblastine sulfate

DRUG

vincristine sulfate

RADIATION

radiation therapy

Sponsors & Collaborators

  • Mount Vernon Cancer Centre at Mount Vernon Hospital

    lead OTHER

Principal Investigators

  • Peter J. Hoskin, MD · Mount Vernon Cancer Centre at Mount Vernon Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-10-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00041210 on ClinicalTrials.gov